Long-Term Outcomes of Teplizumab in Routine Clinical Care
brief summary
This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D. The study will monitor participants receiving teplizumab as part of routine clinical care across multiple sites. Additionally, patient-reported outcomes (PROs) will be evaluated to further assess the treatment's impact on participant's quality of life including emotional and psychosocial aspects associated with T1D. This approach will provide a more comprehensive understanding of how the treatment performs over time and across diverse patient populations, providing valuable insights into the sustained effects of teplizumab and offering a real world picture of its impact on the long-term management of T1D.
detailed description
Enrolled participants will be followed for up to 10 years depending on the time the participants are included after initiating teplizumab treatment.
official title
Long-Term Outcomes of Participants Treated With Teplizumab in Routine Clinical Care